Koenraad Blot
Plus aucun poste en cours
Profil
Koenraad Blot worked as an Executive Director of Clinical Research at Theratechnologies, Inc., Head of Medical Affairs and Clinical Operations at Pfizer Inc., and Chief Medical Officer at TiGenix NV and elbion NV.
He holds a doctorate from Ghent University and an undergraduate degree from the University of Antwerp.
Anciens postes connus de Koenraad Blot
| Sociétés | Poste | Fin |
|---|---|---|
| TIGENIX NV | Directeur Technique/Scientifique/R&D | - |
| THERATECHNOLOGIES INC. | Directeur Technique/Scientifique/R&D | - |
| PFIZER, INC. | Directeur Technique/Scientifique/R&D | - |
elbion NV
 elbion NV Pharmaceuticals: MajorHealth Technology Elbion NV discovers and develops therapeutics for neurological diseases and immunological disorders. It focuses on the discovery and development of new drugs for CNS and immunological diseases. The company was founded by Dr. Thomas Kronbach and Dr. Bernd Kastler in 2002 and is headquartered in Leuven, Belgium. | Directeur Technique/Scientifique/R&D | - |
Formation de Koenraad Blot
| Ghent University | Doctorate Degree |
| University of Antwerp | Undergraduate Degree |
Expériences
Fonctions occupées
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| THERATECHNOLOGIES INC. | Health Technology |
| PFIZER, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
elbion NV
elbion NV Pharmaceuticals: MajorHealth Technology Elbion NV discovers and develops therapeutics for neurological diseases and immunological disorders. It focuses on the discovery and development of new drugs for CNS and immunological diseases. The company was founded by Dr. Thomas Kronbach and Dr. Bernd Kastler in 2002 and is headquartered in Leuven, Belgium. | Health Technology |
TiGenix NV
 TiGenix NV Medical SpecialtiesHealth Technology TiGenix NV engages in the research, development, and commercialization of biopharmaceutical products. The firm's portfolio includes allogeneic adipose-derived stem cells and allogeneic cardiac stem cells. It intends to treat Crohn's disease, sepsis, autoimmune disorders, acute myocardial infarction, and chronic cardiovascular indication. The company was founded by Gil Beyen and Frank P. Luyten on February 21, 2000 and is headquartered in Leuven, Belgium. | Health Technology |
